Schedule 13D ownership disclosure

EVOKE PHARMA INC

Common Stock, par value $0.0001 per share · CUSIP: 30049G203

Event date: 2025-02-03

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Nantahala Capital Management, LLCReported CIK 0001472322

    Shares: 254,639.00 · Class: 15.99%

  • Wilmot B. Harkey

    Shares: 254,639.00 · Class: 15.99%

  • Daniel Mack

    Shares: 254,639.00 · Class: 15.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-008666
Form type
SCHEDULE 13D/A
Filer
Evoke Pharma Inc
CIK
CIK 1403708
Filed
Feb 03, 2025
Reporting period
Feb 03, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub